Ebrahimi-Fakhari Daniel, Müller Cornelia Sigrid Lissi, Meyer Sascha, Flotats-Bastardas Marina, Vogt Thomas, Pföhler Claudia
Department of Pediatrics and Neonatology, Saarland Tuberous Sclerosis Center, Saarland University Medical Center, Homburg/Saar, Germany.
Department of Dermatology, Allergology, and Venereology, Saarland University Medical Center, Homburg/Saar, Germany.
Dermatol Ther (Heidelb). 2017 Mar;7(1):175-179. doi: 10.1007/s13555-017-0174-5. Epub 2017 Feb 8.
Tuberous sclerosis complex (TSC) is a genetic multisystem disorder with prominent skin involvement including facial angiofibromas that often appear in early childhood. Here we report the case of a 12-year-old girl with widespread disfiguring facial angiofibromas that were successfully treated with topical rapamycin, a mTOR inhibitor. A sustained remission of skin lesions was documented in detail over a 3-year follow-up. This case highlights the fact that topical rapamycin is a useful option in treating TSC-associated skin lesions. Especially in medically complex patients topical treatment may lessen the need for surgical interventions, reducing the risks of surgery, its adverse effects and permanent scarring. However, there is no standard dose or formulation at present. Topical rapamycin appears safe, but long-term maintenance therapy is necessary to prevent facial lesions from regrowth.
结节性硬化症(TSC)是一种遗传性多系统疾病,皮肤受累明显,包括常在儿童早期出现的面部血管纤维瘤。在此,我们报告一例12岁女孩,其面部广泛毁容性血管纤维瘤经mTOR抑制剂雷帕霉素局部治疗后获得成功。在3年的随访中详细记录了皮肤病变的持续缓解情况。该病例突出了雷帕霉素局部治疗是治疗TSC相关皮肤病变的一种有效选择这一事实。特别是对于病情复杂的患者,局部治疗可减少手术干预的需求,降低手术风险、其不良反应和永久性瘢痕形成。然而,目前尚无标准剂量或剂型。雷帕霉素局部治疗似乎是安全的,但需要长期维持治疗以防止面部病变复发。